How to Use CagriSema
Complete guide to CagriSema dosing, administration, timing, and protocol recommendations.
Quick Overview
CagriSema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a GLP-1 receptor agonist, the molecule behind Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). It is being developed by Novo Nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 REDEFINE trials. It is not yet approved by the FDA, though regulatory filings are underway.
Dosing Guidelines
Common Dose
Limited community data available
Frequency
See research protocols
Dose Range
See research dosing
Note: Limited anecdotal data. Refer to research dosing section.
Administration Method
Subcutaneous injection weekly
Best Time to Take
Before bed or morning (fasted)
GH-related peptides work best on an empty stomach to maximize growth hormone release.
Protocol Duration
Long-term use expected
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea
- •Vomiting
- •Diarrhea
- •Constipation
- •GI events (72-80% vs 34-40% placebo)
Frequently Asked Questions
What is the recommended dose for CagriSema?
Limited community data available
How do you administer CagriSema?
Subcutaneous injection weekly
When is the best time to take CagriSema?
Before bed or morning (fasted)
How long should you use CagriSema?
Long-term use expected
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.